ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Elanco Animal Health and Ginkgo Bioworks are launching BiomEdit, a company that will use microbiome science to develop drugs, nutritional products, and disease-monitoring methods for livestock. The new firm hopes to address antibiotic resistance and improve sustainability. It is starting up with $40 million in funding from outside investors. Elanco is putting its microbiome R&D initiative into BiomEdit to focus on pet health. Elanco and Ginkgo will have a combined 40% stake in the company.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X